Skip to main content

Advertisement

SpringerLink
Log in

Liquid Biopsy in Primary Brain Tumors: Looking for Stardust!

  • Neuro-Oncology (LE Abrey, Section Editor)
  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Personalized medicine is a challenge to improve survival and quality of life of patients suffering from primary malignant brain tumor. Molecular biology is integrated in initial diagnosis and relapse, and, in the nearest future, over treatment schedule and monitoring. Liquid biopsy is a minimally invasive way to obtain tumor material.

Recent Findings

Over the past years, three fluids have been explored to provide tumor information in primary malignant brain tumor: blood, cerebrospinal fluid, and vitreous liquid. Different tumor components were identified: (1) circulating tumor cells, (2) circulating tumor DNA, (3) RNA and non-coding miRNA, and (4) extracellular vesicles. The performance of the liquid biopsy depends on the tumor type and on the method of detection.

Summary

Liquid biopsy could be a valuable tool to improve patient care in primary malignant brain tumor. Improvement of its sensitivity is the major challenge to generalize its use in daily practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. de Robles P, Fiest KM, Frolkis AD, Pringsheim T, Atta C, St Germaine-Smith C, et al. The worldwide incidence and prevalence of primary brain tumors: a systematic review and meta-analysis. Neuro-Oncology. 2015;17(6):776–83. https://doi.org/10.1093/neuonc/nou283.

    Article  PubMed  Google Scholar 

  2. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–20. https://doi.org/10.1007/s00401-016-1545-1.

    Article  PubMed  Google Scholar 

  3. Hodges TR, Ott M, Xiu J, Gatalica Z, Swensen J, Zhou S, et al. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro-Oncology. 2017;19(8):1047–57. https://doi.org/10.1093/neuonc/nox026.

    Article  PubMed  Google Scholar 

  4. Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16(11):2598–608. https://doi.org/10.1158/1535-7163.MCT-17-0386.

    Article  CAS  PubMed  Google Scholar 

  5. Le DT UJN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20. https://doi.org/10.1056/NEJMoa1500596.

    Article  Google Scholar 

  6. Reardon DA, Lassman AB, van den Bent M, Kumthekar P, Merrell R, Scott AM, et al. Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma. Neuro-Oncology. 2017;19(7):965–75. https://doi.org/10.1093/neuonc/now257.

    PubMed  Google Scholar 

  7. Gan HK, Reardon DA, Lassman AB, Merrell R, van den Bent M, Butowski N, et al. Safety, pharmacokinetics and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma. Neuro-Oncology. 2017; https://doi.org/10.1093/neuonc/nox202.

  8. Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21(8):922–6. https://doi.org/10.1038/nm.3884.

    Article  CAS  PubMed  Google Scholar 

  9. Grommes C, Pastore A, Palaskas N, Tang SS, Campos C, Schartz D, et al. Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma. Cancer Discov. 2017;7(9):1018–29. https://doi.org/10.1158/2159-8290.CD-17-0613.

    Article  CAS  PubMed  Google Scholar 

  10. Mohammad F, Weissmann S, Leblanc B, Pandey DP, Højfeldt JW, Comet I, et al. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas. Nat Med. 2017;23(4):483–92. https://doi.org/10.1038/nm.4293.

    Article  CAS  PubMed  Google Scholar 

  11. Pi C, Zhang M-F, Peng X-X, Zhang Y-C, Xu C-R, Zhou Q. Liquid biopsy in non-small cell lung cancer: a key role in the future of personalized medicine? Expert Rev Mol Diagn. 2017;17(12):1089–96. https://doi.org/10.1080/14737159.2017.1395701.

    Article  CAS  PubMed  Google Scholar 

  12. De Mattos-Arruda L, Caldas C. Cell-free circulating tumour DNA as a liquid biopsy in breast cancer. Mol Oncol. 2016;10(3):464–74. https://doi.org/10.1016/j.molonc.2015.12.001.

    Article  PubMed  Google Scholar 

  13. Jia S, Zhang R, Li Z, Li J. Clinical and biological significance of circulating tumor cells, circulating tumor DNA, and exosomes as biomarkers in colorectal cancer. Oncotarget. 2017;8(33):55632–45. https://doi.org/10.18632/oncotarget.17184.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Masuda T, Hayashi N, Iguchi T, Ito S, Eguchi H, Mimori K. Clinical and biological significance of circulating tumor cells in cancer. Mol Oncol. 2016;10(3):408–17. https://doi.org/10.1016/j.molonc.2016.01.010.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004;10(20):6897–904. https://doi.org/10.1158/1078-0432.CCR-04-0378.

    Article  PubMed  Google Scholar 

  16. • Sullivan JP, Nahed BV, Madden MW, Oliveira SM, Springer S, Bhere D, et al. Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discov. 2014;4:1299–309. This study provides evidence of release of tumor cells in blood in GBM and highlights that the release mechanism is dependent on a phenotype modification.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. • Macarthur KM, Kao GD, Chandrasekaran S, Alonso-Basanta M, Chapman C, Lustig RA, et al. Detection of brain tumor cells in the peripheral blood by a telomerase promoter-based assay. Cancer Res. 2014;74:2152–9. This study develops an original method to detect circulating tumor cells in plasma.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. • Schwaederle M, Chattopadhyay R, Kato S, Fanta PT, Banks KC, Choi IS, et al. Genomic alterations in circulating tumor DNA from diverse cancer patients identified by next-generation sequencing. Cancer Res. 2017;77:5419–27. This study highlights that a targeted NGS panel permits to detect somatic mutations and among them, targetable alterations, in plasma in PMBT.

    Article  CAS  PubMed  Google Scholar 

  19. Fontanilles M, Marguet F, Bohers É, Viailly P-J, Dubois S, Bertrand P, et al. Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma. Oncotarget. 2017;8(29):48157–68. https://doi.org/10.18632/oncotarget.18325.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Hattori K, Sakata-Yanagimoto M, Suehara Y, Yokoyama Y, Kato T, Kurita N, et al. Clinical significance of disease-specific MYD88 mutations in circulating DNA in primary central nervous system lymphoma. Cancer Sci. 2017;

  21. Odjélé A, Charest D, Morin P. miRNAs as important drivers of glioblastomas: a no-brainer? Cancer Biomark. 2012;11(6):245–52. https://doi.org/10.3233/CBM-2012-0271.

    Article  PubMed  Google Scholar 

  22. • Manda SV, Kataria Y, Tatireddy BR, Ramakrishnan B, Ratnam BG, Lath R, et al. Exosomes as a biomarker platform for detecting epidermal growth factor receptor-positive high-grade gliomas. J. Neurosurg. 2017;1–11. This study highlights the use of exosomes in blood to identify high grade glioma using EGFR amplification.

  23. • Figueroa JM, Skog J, Akers J, Li H, Komotar R, Jensen R, et al. Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients. Neuro-Oncol. 2017;19:1494–502. This study is the first to report the two most common EGFR alterations in CSF.

    Article  PubMed  Google Scholar 

  24. • Huang TY, Piunti A, Lulla RR, Qi J, Horbinski CM, Tomita T, et al. Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma. Acta Neuropathol Commun. 2017;5:28. This study describes for the first time the detection of histone mutations H3 in CSF in children and opens the possibility to perform this method in midline gliomas in adults, which are particularly difficult to access surgically.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Akers JC, Hua W, Li H, Ramakrishnan V, Yang Z, Quan K, et al. A cerebrospinal fluid microRNA signature as biomarker for glioblastoma. Oncotarget. 2017;8(40):68769–79. https://doi.org/10.18632/oncotarget.18332.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Cani AK, Hovelson DH, Demirci H, Johnson MW, Tomlins SA, Rao RC. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies. Oncotarget. 2017;8(5):7989–98. https://doi.org/10.18632/oncotarget.14008.

    Article  PubMed  Google Scholar 

  27. Müller C, Holtschmidt J, Auer M, Heitzer E, Lamszus K, Schulte A, et al. Hematogenous dissemination of glioblastoma multiforme. Sci Transl Med. 2014;6(247):247ra101. https://doi.org/10.1126/scitranslmed.3009095.

    Article  PubMed  Google Scholar 

  28. Stroun M, Lyautey J, Lederrey C, Olson-Sand A, Anker P. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta. 2001;313:139–42.

    Article  CAS  PubMed  Google Scholar 

  29. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001;61(4):1659–65.

    CAS  PubMed  Google Scholar 

  30. Aucamp J, Bronkhorst AJ, Peters DL, Van Dyk HC, Van der Westhuizen FH, Pretorius PJ. Kinetic analysis, size profiling, and bioenergetic association of DNA released by selected cell lines in vitro. Cell Mol Life Sci. 2017;74(14):2689–707. https://doi.org/10.1007/s00018-017-2495-z.

    Article  CAS  PubMed  Google Scholar 

  31. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985–90. https://doi.org/10.1038/nm.1789.

    Article  CAS  PubMed  Google Scholar 

  32. Medina Diaz I, Nocon A, Mehnert DH, Fredebohm J, Diehl F, Holtrup F. Performance of Streck cfDNA blood collection tubes for liquid biopsy testing. PLoS One. 2016;11(11):e0166354. https://doi.org/10.1371/journal.pone.0166354.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Norton SE, Lechner JM, Williams T, Fernando MR. A stabilizing reagent prevents cell-free DNA contamination by cellular DNA in plasma during blood sample storage and shipping as determined by digital PCR. Clin Biochem. 2013;46(15):1561–5. https://doi.org/10.1016/j.clinbiochem.2013.06.002.

    Article  CAS  PubMed  Google Scholar 

  34. Steffensen KD, Madsen CV, Andersen RF, Waldstrøm M, Adimi P, Jakobsen A. Prognostic importance of cell-free DNA in chemotherapy resistant ovarian cancer treated with bevacizumab. Eur J Cancer. 2014;50(15):2611–8. https://doi.org/10.1016/j.ejca.2014.06.022.

    Article  CAS  PubMed  Google Scholar 

  35. El Messaoudi S, Mouliere F, Du Manoir S, Bascoul-Mollevi C, Gillet B, Nouaille M, et al. Circulating DNA as a strong multimarker prognostic tool for metastatic colorectal cancer patient management care. Clin Cancer Res. 2016;22(12):3067–77. https://doi.org/10.1158/1078-0432.CCR-15-0297.

    Article  PubMed  Google Scholar 

  36. Yanagita M, Redig AJ, Paweletz CP, Dahlberg SE, O’Connell A, Feeney N, et al. A prospective evaluation of circulating tumor cells and cell-free DNA in EGFR-mutant non-small cell lung cancer patients treated with erlotinib on a phase II trial. Clin Cancer Res. 2016;22(24):6010–20. https://doi.org/10.1158/1078-0432.CCR-16-0909.

    Article  CAS  PubMed  Google Scholar 

  37. Rossi G, Mu Z, Rademaker A, Austin L, Strickland KS, Lima Barros Costa R, et al. Cell-free DNA and circulating tumor cells: comprehensive liquid biopsy analysis in advanced breast cancer. Clin Cancer Res. 2017; https://doi.org/10.1158/1078-0432.CCR-17-2092.

  38. • De Mattos-Arruda L, Mayor R, CKY N, Weigelt B, Martínez-Ricarte F, Torrejon D, et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun. 2015;6:8839. This study was the first to compare diagnostic performance between blood and CSF using NGS in PMBT.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Rothé F, Laes J-F, Lambrechts D, Smeets D, Vincent D, Maetens M, et al. Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. Ann Oncol. 2014;25(10):1959–65. https://doi.org/10.1093/annonc/mdu288.

    Article  PubMed  Google Scholar 

  40. Boisselier B, Gállego Pérez-Larraya J, Rossetto M, Labussière M, Ciccarino P, Marie Y, et al. Detection of IDH1 mutation in the plasma of patients with glioma. Neurology. 2012;79:1693–8.

    Article  CAS  PubMed  Google Scholar 

  41. Fiano V, Trevisan M, Trevisan E, Senetta R, Castiglione A, Sacerdote C, et al. MGMT promoter methylation in plasma of glioma patients receiving temozolomide. J Neuro-Oncol. 2014;117(2):347–57. https://doi.org/10.1007/s11060-014-1395-4.

    Article  CAS  Google Scholar 

  42. Majchrzak-Celińska A, Paluszczak J, Kleszcz R, Magiera M, Barciszewska A-M, Nowak S, et al. Detection of MGMT, RASSF1A, p15INK4B, and p14ARF promoter methylation in circulating tumor-derived DNA of central nervous system cancer patients. J Appl Genet. 2013;54(3):335–44. https://doi.org/10.1007/s13353-013-0149-x.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834–8. https://doi.org/10.1038/nature03702.

    Article  CAS  PubMed  Google Scholar 

  44. Li R, Gao K, Luo H, Wang X, Shi Y, Dong Q, et al. Identification of intrinsic subtype-specific prognostic microRNAs in primary glioblastoma. J Exp Clin Cancer Res. 2014;33(1):9. https://doi.org/10.1186/1756-9966-33-9.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Wei X, Chen D, Lv T, Li G, Qu S. Serum MicroRNA-125b as a potential biomarker for glioma diagnosis. Mol Neurobiol. 2016;53(1):163–70. https://doi.org/10.1007/s12035-014-8993-1.

    Article  CAS  PubMed  Google Scholar 

  46. Regazzo G, Terrenato I, Spagnuolo M, Carosi M, Cognetti G, Cicchillitti L, et al. A restricted signature of serum miRNAs distinguishes glioblastoma from lower grade gliomas. J Exp Clin Cancer Res. 2016;35(1):124. https://doi.org/10.1186/s13046-016-0393-0.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Wang Z-Q, Zhang M-Y, Deng M-L, Weng N-Q, Wang H-Y, Wu S-X. Low serum level of miR-485-3p predicts poor survival in patients with glioblastoma. PLoS One. 2017;12(9):e0184969. https://doi.org/10.1371/journal.pone.0184969.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013;200(4):373–83. https://doi.org/10.1083/jcb.201211138.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Ruivo CF, Adem B, Silva M, Melo SA. The biology of cancer exosomes: insights and new perspectives. Cancer Res. 2017;

  50. Kucharzewska P, Christianson HC, Welch JE, Svensson KJ, Fredlund E, Ringnér M, et al. Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proc Natl Acad Sci U S A. 2013;110(18):7312–7. https://doi.org/10.1073/pnas.1220998110.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Manterola L, Guruceaga E, Gállego Pérez-Larraya J, González-Huarriz M, Jauregui P, Tejada S, et al. A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool. Neuro-Oncology. 2014;16(4):520–7. https://doi.org/10.1093/neuonc/not218.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Chen WW, Balaj L, Liau LM, Samuels ML, Kotsopoulos SK, Maguire CA, et al. BEAMing and droplet digital PCR analysis of mutant IDH1 mRNA in glioma patient serum and cerebrospinal fluid extracellular vesicles. Mol Ther Nucleic Acids. 2013;2:e109. https://doi.org/10.1038/mtna.2013.28.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Pan W, Gu W, Nagpal S, Gephart MH, Quake SR. Brain tumor mutations detected in cerebral spinal fluid. Clin Chem. 2015;61(3):514–22. https://doi.org/10.1373/clinchem.2014.235457.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Baraniskin A, Kuhnhenn J, Schlegel U, Schmiegel W, Hahn S, Schroers R. MicroRNAs in cerebrospinal fluid as biomarker for disease course monitoring in primary central nervous system lymphoma. J Neuro-Oncol. 2012;109(2):239–44. https://doi.org/10.1007/s11060-012-0908-2.

    Article  CAS  Google Scholar 

  55. Baraniskin A, Zaslavska E, Nöpel-Dünnebacke S, Ahle G, Seidel S, Schlegel U, et al. Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for primary central nervous system lymphoma. Neuro-Oncology. 2015;

  56. Drusco A, Bottoni A, Laganà A, Acunzo M, Fassan M, Cascione L, et al. A differentially expressed set of microRNAs in cerebro-spinal fluid (CSF) can diagnose CNS malignancies. Oncotarget. 2015;6(25):20829–39. https://doi.org/10.18632/oncotarget.4096.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Pochat-Cotilloux C, Bienvenu J, Nguyen A-M, Ohanessian R, Ghesquières H, Sève P, et al. Use of a threshold of interleukin-10 and IL-10/IL-6 ratio in ocular samples for the screening of vitreoretinal lymphoma. Retina (Philadelphia, Pa). 2017;

  58. Bonzheim I, Giese S, Deuter C, Süsskind D, Zierhut M, Waizel M, et al. High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma: a valuable tool to improve diagnostic yield of vitreous aspirates. Blood. 2015;126(1):76–9. https://doi.org/10.1182/blood-2015-01-620518.

    Article  CAS  PubMed  Google Scholar 

  59. Noel N, Couteau J, Maillet G, Gobet F, D’Aloisio F, Minier C, et al. TP53 and FGFR3 gene mutation assessment in urine: pilot study for bladder cancer diagnosis. Anticancer Res. 2015;35(9):4915–21.

    CAS  PubMed  Google Scholar 

  60. Kinde I, Munari E, Faraj SF, Hruban RH, Schoenberg M, Bivalacqua T, et al. TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Cancer Res. 2013;73(24):7162–7. https://doi.org/10.1158/0008-5472.CAN-13-2498.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Botezatu I, Serdyuk O, Potapova G, Shelepov V, Alechina R, Molyaka Y, et al. Genetic analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA sequences from cells dying in an organism. Clin Chem. 2000;46(8 Pt 1):1078–84.

    CAS  PubMed  Google Scholar 

  62. Chen S, Zhao J, Cui L, Liu Y. Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients treated with EGFR-TKIs. Clin Transl Oncol. 2017;19(3):332–40. https://doi.org/10.1007/s12094-016-1534-9.

    Article  CAS  PubMed  Google Scholar 

  63. Reckamp KL, Melnikova VO, Karlovich C, Sequist LV, Camidge DR, Wakelee H, et al. A highly sensitive and quantitative test platform for detection of NSCLC EGFR mutations in urine and plasma. J Thorac Oncol. 2016;11(10):1690–700. https://doi.org/10.1016/j.jtho.2016.05.035.

    Article  PubMed  Google Scholar 

  64. Pu D, Liang H, Wei F, Akin D, Feng Z, Yan Q, et al. Evaluation of a novel saliva-based epidermal growth factor receptor mutation detection for lung cancer: a pilot study. Thorac Cancer. 2016;7(4):428–36. https://doi.org/10.1111/1759-7714.12350.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Jamal-Hanjani M, Wilson GA, Horswell S, Mitter R, Sakarya O, Constantin T, et al. Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer. Ann Oncol. 2016;27(5):862–7. https://doi.org/10.1093/annonc/mdw037.

    Article  CAS  PubMed  Google Scholar 

  66. Hohaus S, Giachelia M, Massini G, Mansueto G, Vannata B, Bozzoli V, et al. Cell-free circulating DNA in Hodgkin’s and non-Hodgkin’s lymphomas. Ann Oncol. 2009;20(8):1408–13. https://doi.org/10.1093/annonc/mdp006.

    Article  CAS  PubMed  Google Scholar 

  67. • Underhill HR, Kitzman JO, Hellwig S, Welker NC, Daza R, Baker DN, et al. Fragment length of circulating tumor DNA. PLoS Genet. 2016;12:e1006162. This study explores the mechanism of release of ctDNA in plasma in GBM and provides tools to improve detection method in future studies.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Madhavan D, Wallwiener M, Bents K, Zucknick M, Nees J, Schott S, et al. Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis. Breast Cancer Res Treat. 2014;146(1):163–74. https://doi.org/10.1007/s10549-014-2946-2.

    Article  CAS  PubMed  Google Scholar 

  69. Leng S, Zheng J, Jin Y, Zhang H, Zhu Y, Wu J, et al. Plasma cell-free DNA level and its integrity as biomarkers to distinguish non-small cell lung cancer from tuberculosis. Clin Chim Acta. 2017;

  70. Best MG, Sol N, In ‘t Veld SGJG, Vancura A, Muller M, A-LN N, et al. Swarm intelligence-enhanced detection of non-small-cell lung cancer using tumor-educated platelets. Cancer Cell. 2017;32:238–252.e9.

    Article  CAS  PubMed  Google Scholar 

  71. Krug AK, Enderle D, Karlovich C, Priewasser T, Bentink S, Spiel A, et al. Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma. Ann Oncol. 2017; https://doi.org/10.1093/annonc/mdx765.

  72. Uehiro N, Sato F, Pu F, Tanaka S, Kawashima M, Kawaguchi K, et al. Circulating cell-free DNA-based epigenetic assay can detect early breast cancer. Breast Cancer Res. 2016;18(1):129. https://doi.org/10.1186/s13058-016-0788-z.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors thank Louise Damian for providing graphical support for figure elaboration. The research leading to these results has received funding from the program “Investissements d’Avenir” ANR-10-IAIHU-06, Institut Universitaire de Cancérologie.

Author information

Authors and Affiliations

  1. Normandie Univ, UNIROUEN, Inserm U1245, IRON Group, Normandy Centre for Genomic and Personalized Medicine, Rouen University Hospital, F-76031, Rouen, France

    Maxime Fontanilles

  2. AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, F-75013, Paris, France

    Maxime Fontanilles & Alberto Duran-Peña

  3. Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, F-75013, Paris, France

    Ahmed Idbaih

Authors
  1. Maxime Fontanilles
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alberto Duran-Peña
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ahmed Idbaih
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ahmed Idbaih.

Ethics declarations

Conflict of Interest

A.D.-P. declares no conflict of interest.

M.F. reports non-financial support from Hoffman-La Roche and Amgen and personal fees from “La Lettre du Cancérologue,” outside the submitted work. A.I. reports grants from Fondation ARC, other from IntselChimos, other from Hoffman-La Roche, other from Beta-Innov (July 2014); personal fees from “La Lettre du Cancérologue,” other from Cathera (June 2017), other from BMS (November 2015), other from Hoffman-La Roche (December 2015), other from Cipla (December 2015), outside the submitted work.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical collection on Neuro-oncology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fontanilles, M., Duran-Peña, A. & Idbaih, A. Liquid Biopsy in Primary Brain Tumors: Looking for Stardust!. Curr Neurol Neurosci Rep 18, 13 (2018). https://doi.org/10.1007/s11910-018-0820-z

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11910-018-0820-z

Keywords

Search

Navigation